NEWSROOM
Creative Medical Technology Granted FDA Clearance for Chronic Back Pain Clinical Trial
New York, December 21, 2023 - Creative Medical Technology Holdings, Inc. (Nasdaq: CELZ) has received FDA clearance to conduct a phase 1/2 clinical trial using the company’s innovative StemSpine® treatment known as AlloStem™ (CELZ-201-DDT). https://prismmarketview.com/companies/creative-medical-technology-holdings-inc/ Timothy Warbington, CEO of Creative Medical Technology, said, “The FDA’s clearance and IRB approval allowing us to pursue this clinical trial is another...
Clubhouse Media Group, Inc. Announces Separation from Agency to Focus Resources on HoneyDrip.com
LOS ANGELES, December 21, 2023 - Clubhouse Media Group, Inc. (OTC: CMGR) ("CMGR"), a social media firm, today announced that it has terminated its joint venture agreement with The Reiman Agency so that the company can dedicate its time and resources to the development and continued growth of HoneyDrip.com. Honeydrip.com is a digital platform designed and wholly owned by CMGR with a focus on the empowerment of creators. The site allows creators to connect and engage with fans and monetize...
PRISM BIOTECH IN MOTION: FDA APPROVAL FOR PANBELA THERAPEUTICS PEDIATRIC CANCER DRUG; SHARES JUMP 120%
New York, December 20, 2023 - PRISM MarketView, a leading provider of unbiased market insight and company news, today highlights Panbela Therapeutics, Inc. which has announced that US WorldMeds®1 (USWM) has received FDA approval of its New Drug Application (NDA) for the use of eflornithine as a maintenance therapy for high-risk neuroblastoma patients. In July 2023, Panbela divested its pediatric neuroblastoma program to USWM in an arrangement entitling Panbela to up to approximately $9.5...
PRISM MarketView: Biotech In Motion – Lipella Pharmaceuticals Celebrates Year of Success
New York, December 20, 2023 - Clinical-stage biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO) is celebrating a year of strategic accomplishments on its first anniversary as a public company. Lipella is advancing three clinical indications and has been granted two Orphan Drug Designations by the US Food and Drug Administration (FDA). https://prismmarketview.com/companies/lipella-pharmaceuticals-inc/ Today, the company announced it has successfully completed a Type C meeting with...
Spooz, Inc. (SPZI) Completes Primary Acquisitions and Change of Control
Spooz Acquired Key JP Energy Assets; Vests Control to John K. Park Clearwater, FL., December 20, 2023 -- Spooz, Inc. (OTC: SPZI) completed the acquisition of key JP Energy assets for vesting control of Spooz, Inc. to John K. Park. Additional assets to be announced later in exchange for vesting control of Spooz, Inc. to John K. Park. The first two companies announced as part of these acquisitions are JP Energy Group, Inc. (New Jersey Corporation) and JP Energy Global PTE, LTD (Singapore...
Buy Now, Pay Later: Affirm Shares Jump on News of Walmart Partnership
New York, December 20, 2023 - Shares in payment network company, Affirm Holdings (Nasdaq: AFRM), jumped more than 15% on Tuesday after the company announced it would expand its partnership with Walmart to offer a Buy Now, Pay Later (BNPL) service at self-checkout kiosks at over 4,500 Walmart stores in the United States. https://prismmarketview.com/companies/affirm-holdings-inc/ https://prismmarketview.com/buy-now-pay-later-affirm-shares-jump-on-news-of-walmart-partnership/ Pat Suh, Affirm’s...
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished
-Lipella Granted Two Orphan Drug Designations by FDA- Pittsburgh, PA, December 20, 2023 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company") a pioneering, clinical-stage pharmaceutical company, celebrates its first anniversary as a publicly traded entity. Based in Pittsburgh, PA, the Company has made substantial strides over the past year, achieving critical milestones and advancing its pipeline with three clinical indications and two orphan drug designations...
SinglePoint Announces Closing of $4 Million Public Offering, Uplisting to Cboe Global Markets and Reverse Stock Split
Phoenix, AZ, December 19, 2023 - SinglePoint Inc. (Cboe: SING) (“SinglePoint” or the “Company”), a diversified holding company principally engaged through its subsidiaries in providing renewable energy solutions and energy-efficient applications to drive better health and living, today announced the closing of its underwritten public offering of 800,000 shares of common stock at a public offering price of $5.00 per share. The gross proceeds from the offering, before underwriting discounts...
NRx Pharmaceuticals Secures IND for Urinary Tract Infection Treatment
New York, December 19, 2023 - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has been granted FDA clearance for its Investigational New Drug Application (IND) for NRX-101 for the treatment of complicated Urinary Tract infections (cUTI). The company’s shares surged 25% in trading on Monday following the news. https://prismmarketview.com/companies/nrx-pharmaceuticals-inc/ Complicated Urinary Tract Infections afflict approximately 3 million Americans each year, and pathogens have...
PPJ Healthcare Enterprises, Inc. signed new Billing Accounts
TAMPA, FLORIDA, December 19, 2023 - PPJ Healthcare Enterprises Inc. (OTC Pink: PPJE) has announced today that it closed one billing agreement with a ‘pain management physicians’ group to provide their billing and collections. “We have been successful in providing specialty billing services for over 33 years, and we are very excited to add this group of physicians. The initial term of this agreement is two years. After taking time to sort out issues that held us back, the Company will now...